Objective The aim of this study was to analyze the incidence and mortality of prostate cancer in cancer registra-tion areas of Yunnan province in 2020,as well as its changing trends from 2012 to 2020,and provide suggestions for the prevention and treatment of prostate cancer in Yunnan province.Methods The data of prostate cancer incidence and mortality in cancer regis-tration areas of Yunnan province from 2012 to 2020 were collected and organized.Excel 2016 and SPSS 18.0 software were used to calculate the crude incidence,crude mortality,age-standardized incidence rate by World standard population(ASIRW),age-stand-ardized mortality rate by Chinese standard population(ASMRC),truncated rate,cumulative rate and other indicators.ASIRW and ASMRC were calculated by using Segi's World population composition.Joinpoint 4.8.0.1 software was used to calculate the annual percentage change(APC)and 95%CI of ASIRW and ASMRC of prostate cancer from 2012 to 2020,and analyze their annual change trends.Results In 2020,the crude incidence and ASIRW of male prostate cancer in cancer registration areas of Yunnan province were 9.71/100,000 and 6.21/100,000,respectively.ASIRW in urban areas(7.94/100,000)was higher than that in rural areas(5.48/100,000).In 2020,the crude mortality and ASMRC of male prostate cancer in cancer registration areas of Yunnan province were 4.68/100,000 and 2.87/100,000,respectively.ASMRC in urban areas(3.68/100,000)was higher than that in rural areas(2.53/100,000).In 2020,the incidence and mortality of male prostate cancer in Yunnan province increased with age,were at a low level before the age of 45,and began to rise rapidly after the age of 55.From 2012 to 2020,there was no statistically significant change trend in ASIRW and ASMRC of male prostate cancer in Yunnan province(APC were 1.79%and 3.61%,P>0.05).However,ASIRW and ASMRC of rural males were on the rise(APC were 4.45%and 3.85%,respectively,P<0.05).Conclusion ASIRW and ASMRC of male prostate cancer in cancer registration areas of Yunnan province in 2020 are higher in urban men than those in rural areas.The change trend of ASIRW and ASMRC from 2012 to 2020 is flat,and rural elderly men should be paid more attention.

Objective The aim of this study was to analyze the incidence and mortality of gastric cancer in tumor registration areas of Yunnan province in 2020,as well as the changing trends from 2012 to 2020,and provide suggestion for the prevention and treatment of gastric cancer in Yunnan province.Methods The incidence and death cases of gastric cancer in tumor registration areas of Yunnan province from 2012 to 2020 were collected and complied.After the quality control,the data was included in 89 monitoring points in 2020.Excel 2016 and SPSS 18.0 software were used to calculate the crude incidence,crude mortality,age-standardized inci-dence rate by World standard population(ASIRW),age-standardized mortality rate by World standard population(ASMRW),cumula-tive rate and other indicators of gastric cancer in Yunnan province in 2020.Joinpoint 4.8.0.1 software was used to calculate the annu-al percentage change(APC)and 95%CI of the ASIRW and ASMRW of gastric cancer from 2012 to 2020,and analyze the trend of change.Results In 2020,the crude incidence and ASIRW of gastric cancer in Yunnan province were 11.59/100,000 and 7.60/100,000,respectively.Males(14.90/100,000 and 10.25/100,000)were higher than those in females(8.10/100,000 and 5.04/100,000).In 2020,the crude mortality and ASMRW of gastric cancer in the Yunnan in 2020 were 9.06/100,000 and 5.82/100,000,respectively.Males(11.51/100,000 and 7.89/100,000)were higher than those in females(6.48/100,000 and 3.82/100,000).The crude incidence and mortality of gastric cancer in Yunnan province increased with age.They were at a low level before the age of 45 years old,and then increased rapidly.The 80-84 age group reached the peak(64.12/100,000 and 72.67/100,000),respectively.The APC for ASIRW and ASMRW of gastric cancer in Yunnan province from 2012 to 2020 were-0.35%and 0.22%,re-spectively,there were no significant difference in the trend of change(P>0.05).Conclusion ASIRW and ASMRW of gastric cancer of Yunnan province in 2020 are higher for men than women.The trend of ASIRW and ASMRW maintained stable from 2012 to 2020,and the males and middle-aged elderly people over 45 years old in Yunnan province are the key population for gastric cancer preven-tion and control.

Objective The aim of this study was to analyze the incidence and mortality of prostate cancer in cancer registra-tion areas of Yunnan province in 2020,as well as its changing trends from 2012 to 2020,and provide suggestions for the prevention and treatment of prostate cancer in Yunnan province.Methods The data of prostate cancer incidence and mortality in cancer regis-tration areas of Yunnan province from 2012 to 2020 were collected and organized.Excel 2016 and SPSS 18.0 software were used to calculate the crude incidence,crude mortality,age-standardized incidence rate by World standard population(ASIRW),age-stand-ardized mortality rate by Chinese standard population(ASMRC),truncated rate,cumulative rate and other indicators.ASIRW and ASMRC were calculated by using Segi's World population composition.Joinpoint 4.8.0.1 software was used to calculate the annual percentage change(APC)and 95%CI of ASIRW and ASMRC of prostate cancer from 2012 to 2020,and analyze their annual change trends.Results In 2020,the crude incidence and ASIRW of male prostate cancer in cancer registration areas of Yunnan province were 9.71/100,000 and 6.21/100,000,respectively.ASIRW in urban areas(7.94/100,000)was higher than that in rural areas(5.48/100,000).In 2020,the crude mortality and ASMRC of male prostate cancer in cancer registration areas of Yunnan province were 4.68/100,000 and 2.87/100,000,respectively.ASMRC in urban areas(3.68/100,000)was higher than that in rural areas(2.53/100,000).In 2020,the incidence and mortality of male prostate cancer in Yunnan province increased with age,were at a low level before the age of 45,and began to rise rapidly after the age of 55.From 2012 to 2020,there was no statistically significant change trend in ASIRW and ASMRC of male prostate cancer in Yunnan province(APC were 1.79%and 3.61%,P>0.05).However,ASIRW and ASMRC of rural males were on the rise(APC were 4.45%and 3.85%,respectively,P<0.05).Conclusion ASIRW and ASMRC of male prostate cancer in cancer registration areas of Yunnan province in 2020 are higher in urban men than those in rural areas.The change trend of ASIRW and ASMRC from 2012 to 2020 is flat,and rural elderly men should be paid more attention.

Objective The aim of this study was to analyze the incidence and mortality of gastric cancer in tumor registration areas of Yunnan province in 2020,as well as the changing trends from 2012 to 2020,and provide suggestion for the prevention and treatment of gastric cancer in Yunnan province.Methods The incidence and death cases of gastric cancer in tumor registration areas of Yunnan province from 2012 to 2020 were collected and complied.After the quality control,the data was included in 89 monitoring points in 2020.Excel 2016 and SPSS 18.0 software were used to calculate the crude incidence,crude mortality,age-standardized inci-dence rate by World standard population(ASIRW),age-standardized mortality rate by World standard population(ASMRW),cumula-tive rate and other indicators of gastric cancer in Yunnan province in 2020.Joinpoint 4.8.0.1 software was used to calculate the annu-al percentage change(APC)and 95%CI of the ASIRW and ASMRW of gastric cancer from 2012 to 2020,and analyze the trend of change.Results In 2020,the crude incidence and ASIRW of gastric cancer in Yunnan province were 11.59/100,000 and 7.60/100,000,respectively.Males(14.90/100,000 and 10.25/100,000)were higher than those in females(8.10/100,000 and 5.04/100,000).In 2020,the crude mortality and ASMRW of gastric cancer in the Yunnan in 2020 were 9.06/100,000 and 5.82/100,000,respectively.Males(11.51/100,000 and 7.89/100,000)were higher than those in females(6.48/100,000 and 3.82/100,000).The crude incidence and mortality of gastric cancer in Yunnan province increased with age.They were at a low level before the age of 45 years old,and then increased rapidly.The 80-84 age group reached the peak(64.12/100,000 and 72.67/100,000),respectively.The APC for ASIRW and ASMRW of gastric cancer in Yunnan province from 2012 to 2020 were-0.35%and 0.22%,re-spectively,there were no significant difference in the trend of change(P>0.05).Conclusion ASIRW and ASMRW of gastric cancer of Yunnan province in 2020 are higher for men than women.The trend of ASIRW and ASMRW maintained stable from 2012 to 2020,and the males and middle-aged elderly people over 45 years old in Yunnan province are the key population for gastric cancer preven-tion and control.

BACKGROUNDOveractive bladder (OAB) is a series of symptoms with high prevalence in elderly people. This study was conducted using the overactive bladder symptom score (OABSS) to evaluate the efficacy of solifenacin succinate for the treatment of OAB.

METHODSThis was a prospective, multicenter, single-arm, 12-week study that enrolled 241 OAB patients. The patients received 5-10 mg/day solifenacin. Changes in OABSS, symptoms from voiding diary, perception of bladder condition (PPBC) score, international prostate symptom score (IPSS) and quality of life (QOL) were evaluated at weeks 0, 4, and 12. The relationship between OABSS and PPBC score or parameters of voiding diary was also evaluated.

RESULTSAt baseline, the mean OABSS for all patients was 9.41 ± 2.40, and was reduced significantly at week 12 (-3.76 points; 61.21%, P < 0.0001). The OABSS subscore, PPBC score, IPSS, and QOL were also significantly reduced during the study (P < 0.0001). The overall incidence of adverse events was 19.91% (44 cases). The gastrointestinal system was the most commonly affected (11.31%). Around 5.88% of the cases had adverse events related to the genitourinary system. There was a strong correlation between OABSS and urinary symptoms that was recorded in the 3-day voiding dairy.

CONCLUSIONSWe showed that solifenacin was clinically effective for relieving OAB symptoms, considering the balance between efficacy, patients' well-being, and tolerability. OABSS integrates four OAB symptoms into a single score and can be a useful tool for research and clinical practice.

Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Muscarinic Antagonists ; therapeutic use ; Prospective Studies ; Quality of Life ; Quinuclidines ; therapeutic use ; Solifenacin Succinate ; Tetrahydroisoquinolines ; therapeutic use ; Treatment Outcome ; Urinary Bladder, Overactive ; drug therapy

Objective To discuss the utility of contrast-enhanced ultrasonography (CEUS) in the assessment of treatment efficacy of radiofrequency ablation (RFA) in patients with renal tumors.Methods Forty-seven patients (40 renal cell carcinomas and 7 angiomyolipomas of kidney) with 49 renal tumors were treated with RFA. Tumors were ablated by laparoscopy-assisted (n= 30) and open surgical (n= 17) RFA. The CEUS and contrast-enhanced CT were performed 1 week after treatment to assess the necrotic area. Technical success was defined as elimination of areas that enhanced at imaging within the entire tumor. Results Forty-seven (95. 9%) of 49 tumors were successfully ablated. The mean length of the major axis at the maximal necrotic area was 4. 6 cm. Compared with the lesions before RFA, the necrotic areas were bigger in 45 patients, identical in 3 patients, and smaller in 1 patient. Six lesions showed a residual enhancement at the portion adjacent to the normal renal parenchyma on follow-up CEUS, while 2 were confirmed by CT scans. The sensitivity and specificity of CEUS for detection of residual tumors were 100. 0% and 91.8%, respectively. All patients survived in the follow-up period ranging from 4 to 21 months. Conclusion CEUS combined with CT could be useful for evaluating treatment efficacy of RFA for renal tumors.